Skip to main content
. 2023 Feb 10;23:64. doi: 10.1186/s12883-023-03101-0

Table 1.

The comprassion of the basal demographic and laboratory findings and MLR, PLR, NLR, SII values of patient and control groups

Patient Group Control Group(n = 94) p
Total(n = 186) Active Lesion( +)(n = 99) Active Lesion(-)(n = 87)
Age(year) (mean ± SD) 33.21 ± 7.6 33.85 ± 9.6 32.72 ± 7.38 33.44 ± 8.04 b0.656
Gender(female(n,%)) 141(75.8%) 73 (73.7%) 68 (78.2%) 65 (69.1) c0.392
Disease Duration(year)(mean ± SD) 5.05 ± 4.65 - - -
EDSS(mean ± SD) 1.11 ± 0.49 - - -
Lesion count

1–5: 54 (54.5%)

6–10: 16(16.2%)

 ≥ 11: 29 (29,3%)

Lesion localisation -

Supratentorial:77(77.8%)

Infratentorial:17(17.2%)

Spinal:5(5.1%)

- -

CRP(mg/dL)

(median(min–max))

2.3 (0.1–9.8) 2.1 (0.1–9.8) 2.4 (0.1–8.5) 2.4(1–7.1) b0.425
Monocyte count(109/L) (mean ± SD) 0.42 ± 0.19 0.50 ± 0.23 0.42 ± 0.17 0.34 ± 0.10 b 0.001**
Lymphocyte count(109/L) (median(min–max)) 2.2 (0.9–4) 1.8 (0.9–2.9) 2.2 (0.9–3.5) 2.6 (1.4–4) a 0.001**

Platelet count(109/L)

(mean ± SD)

281.11 ± 69.06 330.72 ± 63.74 285.92 ± 54.99 224.41 ± 36.62 b0.001**
Eosinophil count(109/L) (median(min–max)) 0.1 (0–0.4) 0.1 (0–0.4) 0.1 (0–0.4) 0.1 (0–0.2) a0.104
Neutrophil count(109/L) (median(min–max)) 3.6 (1–14) 4.2 (2.1–14) 3.6 (1–14) 3.1 (1–4.9) a 0.001**
MLR(median(min–max)) 0.2 (0–1.3) 0.3 (0.1–1.3) 0.2 (0–0.7) 0.1 (0–0.3) a0.001**
PLR(median(min–max)) 122.8 (43.2–421.8) 189.8 (83.8–421.8) 135 (61.3–351.3) 89.3 (43.2–189) a0.001**
NLR(median(min–max)) 1.5 (0.4–10.6) 2.5 (1–10.6) 1.5 (0.5–10.6) 1.2 (0.4–2.8) a0.001**
SII(median(min–max)) 452.7 (71.1–3215.6) 797.9 (273–3215.6) 478.1 (151.9–3215.6) 234.2 (71.1–674) a0.001**

EDSS Expanded Disability Status Scale, CRP C- Reactive protein, MLR Monocyte/ lymphocyte ratio, PLR Platelet/ lymphocyte ratio, NLR Neutrophil / lymphocyte ratio, SII Systemic immune-inflammatory index

aKruskal Wallis Test; bOne Way Anova Test; CFisher Freeman Halton Test All values are presented mean ± standard deviation(SD) or median value (min–max); **p<0.05